Currently, the pharmaceutical industry, recognizing the pleiotropic effects of gastrointestinal hormones in regulating metabolic homeostasis, is developing various synthetic drugs, especially GLP-1 receptor agonists and dual GLP-1/GIP agonists, to improve the management of obesity and related metabolic diseases [33]. This evidence concerns the gene GLP1R and obesity disorder.